Tuesday, May 3, 2016

Cryoport, Inc. (CYRX) Continues to Strengthen Sector Footprint with Strategic Deals

Cryoport, Inc. (NASDAQ: CYRX) has developed one of the most comprehensive solution platforms available today in the life sciences-focused cryogenic logistics space, with a suite of proprietary technologies such as its signature Cryoport Express® (http://dtn.fm/jGrs5) dry vapor dewars for materials that need to be kept at frozen temperatures, as well as its Cryoportal™ logistics management platform and SmartPak II™ continuous, geo-sensing monitoring system (http://dtn.fm/53nP7). Reinforced by a rock-solid commitment to 24/7 customer support and cold chain logistics consulting spanning risk assessment, lane qualification and process flow – the company’s portfolio of industry-leading technologies has propelled CYRX to the forefront of the sector, allowing the company to secure such sweetheart deals as the recent strategic partnership with $2.4 billion market cap, diversified metals manufacturing giant, Worthington Industries (NYSE: WOR).

This latest deal will see Worthington’s CryoScience by Taylor Wharton Division, one of the most influential and competent manufacturers in the space today, designing and manufacturing biostorage and logistics hardware for CYRX’s life sciences solutions. It’s the kind of cozy deal that will open big doors for the company, granting its already much sought after cold chain logistics solutions the ability to satisfy a much broader client mix, and enabling the company to dynamically scale support for proliferating client commercialization efforts.

Cryoport is no stranger to marching into the gap like this, as news of the Worthington partnership came just days after the company’s announcement on April 11 regarding the launch of its new Temperature Controlled Logistics Consulting Division, which was organized to answer feverish demand from a global and burgeoning cellular-based therapies market. The deluge of cell-based immunotherapy technologies currently in the soon-to-be $2.45 trillion-plus personalized medicine pipeline (http://dtn.fm/rm0Kj) has created a perfect storm for storage and transportation logistics players and only a tiny handful of key players, such as CYRX, are positioned to capitalize on runaway demand for the kind of planning and strategies needed to help effectively develop and deploy temperature sensitive/personalized therapies.

The broader global cryogenic equipment market is on-track to hit upwards of $25 billion by 2022 (http://dtn.fm/VwY57), with the Asia-Pacific region seen as the strongest segment at around $7.83 billion projected by 2019 (http://dtn.fm/sa9FD). This is a target-rich environment for a company like Cryoport, which is actively working in regenerative medicine in support of some 64 different clinical trials, including Perseus PCI’s Phase II2b melanoma and ovarian cancer clinical trial, as well as ImmunoCellular Therapeutics’ (NYSE: IMUC) registrational Phase III clinical trial of ICT-107 immunotherapy in aggressive brain cancer, which spans 400-plus newly-diagnosed glioblastoma patients at 120 sites throughout North America and Europe.

Any questions as to just how capable Cryoport is when it comes to securing additional traction within the space, should be quickly put to rest by one look at the company’s earlier deal in March of 2016 with one of the planet’s undisputed leaders in logistics, UPS (NYSE: UPS). UPS launching its biotech, pharma and medical device industry-tailored Temperature True® Cryo solution in Europe, which allows customers to keep products at -150°C for 10 days using Cryoport Express containers’ dry vapor liquid nitrogen technology, gives CYRX access to the global network of 51 UPS healthcare-dedicated facilities, and sets the company up for continued success alongside UPS, which serves more than 220 countries and territories worldwide.

For more information, visit www.cryoport.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html